Akoya Biosciences Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2025 to a ratio of 5.79, above the company average. This is a clear sign of healthy business climate in the Laboratory Analytical Instruments industry and improving liquidity at their respective customers, during the first quarter 2025. Average receivable collection period, for the Akoya Biosciences Inc in Mar 31 2025 quarter, has decreased to 63 days, compared to 64 days, in the Dec 31 2024 quarter.

If we take a look into Healthcare sector 226 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1701, from overall ranking in the fourth quarter 2024 at 2247.

What is Receivable Turnover Ratio?
What is Akoya Biosciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AKYA Receivables Turnover Ratio	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Receivable Change	-12.85 %	30520 %	-20.56 %	28.66 %	4.09 %
Y / Y Revenue Change	-8.68 %	-15.47 %	-22.87 %	-3.16 %	-18.83 %
Receivable Turnover Ratio (TTM)	5.79	5.72	7.93	7.84	8.59
AKYA's Total Ranking	# 1701	# 2247	# 2331	# 1575	# 1604
Accounts Receivable average collection period days	63	64	46	47	42
Seq. Receivable Change	-14.78 %	7.77 %	-22.76 %	22.87 %	29840 %
Seq. Revenue Change	-29.11 %	19.57 %	-16.36 %	28.81 %	-34.39 %

Receivable Turnover Company Ranking
Within:	No.
Laboratory Analytical Instruments Industry	# 8
Healthcare Sector	# 227
Overall Market	# 1701

Receivable Turnover Ratio Statistics
High	Average	Low
0.62	0.46	0.31
(Mar 31 2025)		(Mar 31 2022)

AKYA Company Profile • Back to AKYA Efficiency Comparisons • Compare AKYA Receivables Turnover Ratio to its Competitors

Financial Statements
Akoya Biosciences Inc 's Accounts Receivable	$ 12 Millions	Visit AKYA's Balance sheet
Akoya Biosciences Inc 's Sales TTM	$ 79 Millions	Visit AKYA's Income Statement
Sources of AKYA's Revenues		Visit AKYA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Laboratory Analytical Instruments Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
AKYA's Receivable Turnover Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
AKYA's Growth Rates	AKYA's Roa	AKYA's Inventory Turnover Ratio	AKYA's Dividend Comparisons
AKYA's Profitability Ratios	AKYA's Roi	AKYA's Asset Turnover Ratio	AKYA's Dividend Growth
AKYA's Valuation Ratios	AKYA's Roe	AKYA's Financial Strength Ratios	AKYA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2025	Receivable at quarter ending Mar 31 2025
Innovage Holding Corp	17.76	$ 831.684 Millions	$ 46.837 Millions
Talkspace Inc	17.56	$ 193.386 Millions	$ 11.012 Millions
Milestone Scientific Inc	17.43	$ 8.418 Millions	$ 0.483 Millions
Innoviva Inc	17.30	$ 408.353 Millions	$ 23.598 Millions
Neuraxis Inc	17.06	$ 2.935 Millions	$ 0.172 Millions
Novavax inc	17.00	$ 1,254.962 Millions	$ 73.803 Millions
Bellevue Life Sciences Acquisition Corp	16.92	$ 3.381 Millions	$ 0.200 Millions
Pluri Inc	16.81	$ 1.034 Millions	$ 0.062 Millions
Generation Bio Co	15.93	$ 24.556 Millions	$ 1.541 Millions
Petvivo Holdings Inc	15.90	$ 1.133 Millions	$ 0.071 Millions
Zomedica Corp	15.35	$ 27.377 Millions	$ 1.783 Millions
Scienture Holdings Inc	15.32	$ 0.147 Millions	$ 0.010 Millions
Ontrak Inc	15.28	$ 9.890 Millions	$ 0.647 Millions
Quipt Home Medical Corp	15.17	$ 425.431 Millions	$ 28.053 Millions
Kiniksa Pharmaceuticals International Plc	15.14	$ 481.166 Millions	$ 31.782 Millions
China Pharma Holdings Inc	14.95	$ 4.295 Millions	$ 0.287 Millions
Mannkind Corporation	14.48	$ 297.595 Millions	$ 20.559 Millions
Icu Medical Inc	14.25	$ 2,419.911 Millions	$ 169.876 Millions
Inmed Pharmaceuticals Inc	14.25	$ 4.515 Millions	$ 0.317 Millions
Co diagnostics Inc	14.01	$ 3.498 Millions	$ 0.250 Millions
Absci Corp	13.92	$ 4.815 Millions	$ 0.346 Millions
Lipella Pharmaceuticals Inc	13.76	$ 0.520 Millions	$ 0.038 Millions
Biofrontera Inc	13.45	$ 59.599 Millions	$ 4.431 Millions
Dyadic International Inc	13.39	$ 3.554 Millions	$ 0.265 Millions
Lftd Partners Inc	13.23	$ 35.782 Millions	$ 2.704 Millions
Grail Inc	13.17	$ 130.711 Millions	$ 9.925 Millions
Rosecliff Acquisition Corp I	13.04	$ 29.581 Millions	$ 2.268 Millions
Day One Biopharmaceuticals Inc	13.02	$ 161.922 Millions	$ 12.440 Millions
Ptc Therapeutics inc	12.99	$ 1,772.758 Millions	$ 136.420 Millions
Nrc Health	12.99	$ 141.298 Millions	$ 10.874 Millions

Date modified: 2026-09-08T15:11:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.